Oncogenic KRAS-mutant lung cancers remain treatment refractory. A better understanding of the immune response of KRAS-mutant lung cancers is required to facilitate the development of potential therapeutic strategies. Regulatory T cells (Tregs) are a subset of immune cells that promote tumor progression through suppressing anti-tumor immune response. https://www.roneverhart.com/Arjo-Sara-Stedy-Stand-Assist-Manual-Patient-Standing-Aid/